A phase I study of cisplatin ip and carboplatin iv with G-CSF in patients with ovarian cancer

We conducted a dose-escalation study with a fixed dose of intraperitoneal c isplatin and G-CSF support of carboplatin using the Calvert formula in epit helial ovarian cancer. Twenty-five patients were entered in this study. On day I, carboplatin was administered intravenously at target AUCs of 4, 5, 6 , and 7. On day 2, cisplatin was given i.p. in 70 mg/m(2). G-CSF, 50 mu g/m (2), was administered subcutaneously from day 7 to 16. Cycles were schedule d to be delivered every four weeks. A total of 85 cycles were administered. The maximum tolerated dose was AUC 7 mg/ml x min of carboplatin. The overa ll response rate was 80% (12/15). The combination in this regimen is feasib le, and a phase II study of this regimen is warranted.